Moneycontrol PRO
Black Friday Sale
Black Friday Sale
HomeNewsBusinessDr Reddy's launches generic version of Sapropterin Dihydrochloride tablets in US market

Dr Reddy's launches generic version of Sapropterin Dihydrochloride tablets in US market

This product demonstrates that the company is actively expanding the breadth of its portfolio with a treatment for a rare disease, he added.

October 03, 2020 / 13:25 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Dr Reddy's Laboratories on Saturday said it has launched in the US market a generic version of Sapropterin Dihydrochloride tablets that are used to bring down blood phenylalanine (Phe) levels in patients.

    "We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for oral use, illustrating our continued commitment to bring affordable generic medicines to market for patients," Dr Reddy''s Laboratories Chief Executive Officer, North America Generics, Marc Kikuchi, said in a statement.

    This product demonstrates that the company is actively expanding the breadth of its portfolio with a treatment for a rare disease, he added.

    "We are pleased to provide financial support to patients by offering a co-pay card program for eligible patients, details will be available on our website," Kikuchi said.

    The Hyderabad-based company said its Sapropterin Dihydrochloride tablets in 100 mg strength were available in bottle count sizes of 120.

    PTI
    first published: Oct 3, 2020 01:25 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347